Scholarly Articles on Reta

[keangkong]

Below are some hyperlinked articles without pay walls on retatrutide. The article by Jastreboff, et al., describes a 48-week, phase 2 trial of reta.

Abdul-Rahman, et al., The power of three - Retatrutide's role in modern obesity and di, https://doi.org/10.1016/j.ejphar.2024.177095.

Alfaris, et al. (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity - a narrative review. EClinicalMedicine, 75, 102782.

Ansari, et al. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447-459, Rev Endocrinol 20, 447–459.

Bailey, et al. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides 173, 171149.

Brzozowska, et al. (2024). Retatrutide-revolutionary recently developed GLP agonist-literature review. Quality in Sport, 15, 52125-52125.

Deravi, et al., The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity (2024) 40(6) J. Pharm. Technol. 300.

Gutgesell , et al. (2024). Dual and Triple Incretin-Based Co-agonists - Novel Therapeutics for Obesity and Diabetes (2024) Diabetes Therapy, 15, 1069–1084.

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526.

Kaur & Misra (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669-676.

Le Roux & Mondoh (2024). Treatment of obesity with medications binding the glucagon-like peptide 1 receptor - what is the current state of play[Q] Expert Opinion on Pharmacotherapy, 25(2), 131-138.

Martins, et al. (2024). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus. Exploration Drug Sci., 2, 126-143.

Moiz, et al. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine.

Otvos (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 19(8), 869-872.

Pasqualotto, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers - A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 24, 100321.

Rosenkilde (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67-68.

Rosenstock, et al., Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes - a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial
conducted in the USA (2023) The Lancet, 402(10401), 529–544.

Ruder, At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide (2024) 331(1) JAMA 9.

Sanyal, et al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease - a randomized phase 2a trial (2024) 30 Nature Medicine 2037.

Sutherby, It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way (Jun. 3, 2024) 34(6) Managed Healthcare Executive.

Tetelbaun, et al., The First Triple Agonist for Antiobesity - Retatrutide (pre-publication, 2024) Cardiology in Review.

Urva, et al., LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes - a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022) 400(10366 Lancet 1869.

2025-01-10: Edited twice to include several more sources.

 

[DwightTheDelight]

I'm going to click your links, Kongy, but if this is primate porn....again ...

 

[keangkong]

I'm going to click your links, Kongy, but if this is primate porn....again ...

There is difference between erotic and pornographic.

 

[keangkong]

I edited the original post to include several more articles on reta. I can't post on actual experiences since I haven't started on it yet. Actually, my body is doing better on tirzepatide than it did previously and I'm not sure that I'll end up using the reta I bought. But I'm still interested because it's my Plan B.

 

[keangkong]

I'm adding two more articles. Both discuss more than one drug but discuss reta.

Rosenkilde (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67-68, doi.org/10.1038/s41574-023-00938-w.

Ansari, et al. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447-459, Rev Endocrinol 20, 447–459. doi.org/10.1038/s41574-024-00979-9.

 

[keangkong]

Here is an updated list, part I:

List of Reta Sources

Abouelmagd, et al. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment - a systematic review and meta-analysis of randomized controlled trials. Baylor Univ. Med. Ctr. Proceedings, 38(3) 291-303, pmc.ncbi.nlm.nih.gov/articles/PMC12026077/.

Abdul-Rahman, et al., The power of three - Retatrutide's role in modern obesity and diabetes therapy (2024) 985 Eur. J. Pharmacol. 177095.

Alfaris, et al. (2024) GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity - a narrative review. EClinicalMedicine, 75, 102782.

Anderson, (2025). Emerging concepts in obesity management - focus on glucagon receptor agonist combinations. Drugs Context, 2025-14, 4-8.

Ansari, et al. (2024). Targeting the incretin system in obesity and type 2 diabetes mellitus. Nature Reviews Endocrinology, 20, 447-459, Rev Endocrinol 20, 447–459. doi.org/10.1038/s41574-024-00979-9.

Aktas (2025). A Scoping Review on Recent Advances in Antidiabetic Medications - From GLP-1 Receptor Agonists to Dual and Triple Agonists. Advances Clin. Pharmacology & Therapeutics 2(2), 47.

Ault, Retratrutide Produces Greatest Weight Loss (Jan. 7, 2025) Medscape.

Bailey, et al. (2024). Recent advances in peptide-based therapies for obesity and type 2 diabetes. Peptides 173, 171149.

Berkovic, et al. (2025). Saving muscle while losing weight - A vital strategy for sustainable results while on glucagon-like peptide-1 related drugs. World journal of diabetes, 16(9), 109123.

Bhat, et al. (2025). Efficacy and safety of incretin co-agonists - Transformative advances in cardiometabolic healthcare. World J. Cardiol., 17(8), 107991.

Bisson, et al (2023). Letter - Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New Engl. J. Med. 389(17), 1628.

Brzdęk & Brzdęk (2025). Analysis of the safety profile of retatrutide based on phase I and II clinical trials. Lekarz Wojskowy 103(3), 167-175.

Brzozowska, et al. (2024). Retatrutide-revolutionary recently developed GLP agonist-literature review. Quality in Sport, 15, 52125-52125.

Ciardullo, et al. (2024). Advancements in pharmacological treatment of NAFLD-MASLD - a focus on metabolic and liver-targeted interventions. Gastroenterology Rep. 12, goae029.

Concepción-Zavaleta, et al. (2025). Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease - An updated review. World J. Gastroentereol., 31(37), 111435.

Coskun, et al. (2022). LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss - From discovery to clinical proof of concept. Cell Metabolism 34(9), 1234-1247.e9 [retatrutide is 2.9 times less potent than human glucagon at GCGR, 8.9 times more potent at GIPR than human GIP, and GLP-1 is 2.5 times less potent than human GLP-1].

Coskun, et al. (2024). Retatrutide, a triple GIP-GLP-1-glucagon receptor agonist, provides robust HbA1c and body weight reductions to people with type 2 diabetes - a 36--week, phase 2 study. Diabetologie und Stoffwechsel, 19(S 01), S72-S73.

Coskun, et al. (2025). Effects of retatrutide on body composition in people with type 2 diabetes - a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinology 13, 674.

Deravi, et al., The “Weight” for a New Agent Is Almost Over: A Commentary on the Novel Triagonist Retatrutide for Obesity (2024) 40(6) J. Pharm. Technol. 300.

Doggrell (2023). Is retatrutide (LY3437943), a GLP-1, GIP, and glucagon receptor agonist a step forward in the treatment of diabetes and obesity[Q] Expert opinion on investigational drugs, 32(5), 355-359.

Doggrell (2023). Retatrutide showing promise in obesity (and type 2 diabetes). Expert Opn. Investigational Drugs 32(11), 997-1001.

Drucker (2024). Efficacy and Safety of GLP-1 Medicines for Type 2 Diabetes and Obesity. Diabetes Care 47(11), 1873-1888.

Elfeki & Alkhouri (2023). Letter - Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New Engl. J. Med. 389(17), 1629.

Giblin, et al. (pre-publication, 2025). Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis - Rationale and design of the TRIUMPH registrational clinical trials. Diabetes Obesity & Metabolism.

Goetz, et al. (2025). Perceived benefits of treatment for obesity with retatrutide - A qualitative study of patients in a phase 2 clinical trial. Obesity Pillars 16, 100220.

Goldney, et al. (2025). Triple Agonism Based Therapies for Obesity. Curr. Cardiovascular Risk Reps., 19(18), 17.

Guo, et al. (2025) Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction - A model-based meta-analysis of placebo-controlled trials. Obesity Pillars 13, 100162.

Gutgesell , et al. (2024). Dual and Triple Incretin-Based Co-agonists - Novel Therapeutics for Obesity and Diabetes (2024) Diabetes Therapy, 15, 1069–1084.

.

 

[keangkong]

Here is an updated list, part II:

List of Reta Sources

Hong & Choi (2024). Gut Hormones and appetite regulation. Curr. Opn. Endocrinology Diabetes & Obesity 31(3), 115-121.

Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389(6), 514–526. Research Summary: Protocol; Supplementary Appendix. https://doi.org/10.1056/nejmoa2301972.

Jastreboff, et al (2023). Reply to Letter - Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New Engl. J. Med. 389(17), 1629-1630.

Kanu, et al. (2025-09-08, pre-publication). Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes - Results of a phase 2 study. Diabetes Obesity & Metabolism, https://doi.org/10.1111/dom.70097.

Katsi, et al. (2025). Retatrutide—A Game Changer in Obesity Pharmacotherapy. Biomolecules 15(6), 796. ["This molecule is more potent at the human GIP receptor (EC50: 0.0643 nM) and less potent at the GLP-1 (EC50: 0.775 nM) and glucagon (EC50: 5.79 nM) receptors [35]."]

Kaur & Misra (2024). A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur. J. Clin. Pharmacol. 80, 669-676.

Kokkorakis, et al. (2025). Emerging pharmacotherapies for obesity - A systematic review. Pharmacological Rev. 77(1), 100002.

Le Roux & Mondoh (2024). Treatment of obesity with medications binding the glucagon-like peptide 1 receptor - what is the current state of play[Q] Expert Opinion on Pharmacotherapy, 25(2), 131-138.

Li, et al. (2024). Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide. Cell Discovery 10(1), 77.

Marathe, et al. (2025). Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progression. npj Metab Health Dis 3, 10.

Marey, et al. (2025). Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment - a systematic review and meta-analysis of randomized controlled trials. Baylor Univ. Med. Ctr. Proceedings, 38(3) 291-303.

 

[keangkong]

​

Here is an updated list, part III:

List of Reta Sources

Martins, et al. (2024). Glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide agonists for the treatment of obesity and diabetes mellitus. Exploration Drug Sci., 2, 126-143, doi.org/10.37349/eds.2024.00039.

Melson, et al. (2025). What is the pipeline for future medications for obesity[Q] Int'l J. Obesity 49, 433–451.

Misra, et al. (2025). Efficacy and safety of retatrutide for the treatment of obesity - a systematic review of clinical trials. J. Basic & Clin. Physiol. & Pharmacol., 36(4), 263.

Moiz, et al. (2025). Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes. Annals of Internal Medicine. https://doi.org/10.7326/annals-24-01590.

Olowo-Oribi (pre-publication, 2025). Efficacy of Tirzepatide, Retatrutide, and Semaglutide for Weight Loss in Obese Individuals Without Diabetes. Academic Emerg. Med., https://doi.org/10.1111/acem.70088.

Otvos (2024). The latest trends in peptide drug discovery and future challenges. Expert Opinion on Drug Discovery, 19(8), 869-872.

Pasqualotto, et al. (2024). Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers - A systematic review and meta-analysis of randomized controlled trials. Metabolism Open, 24, 100321.

Ray (2023). Retatrutide - A triple incretin receptor agonist for obesity management. Expert Opn. Investigational Drugs, 32(11), 1003-1008.

Ramsbacher (2024). Retatrutide. Clin. Diabetes 42(4), 579-580.

Rosenkilde (2024). Advances in incretin-based therapeutics for obesity. Nature Reviews Endocrinology, 20, 67-68.

Rosenstock, et al., Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes - a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA (2023) The Lancet, 402(10401), 529–544.

Ruder, At ObesityWeek, More Data and Questions About Semaglutide, Tirzepatide, and Retatrutide (2024) 331(1) JAMA 9.

Salhab, et al. (2025). SUN-659 Comparative Efficacy and Safety of Tirzepatide vs Retatrutide in Weight Loss - A Network Meta-Analysis of Clinical Trials. J. Endocrine Soc. 9(Supplement_1), bvaf149-169.

Sanyal, et al., Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease - a randomized phase 2a trial (2024) 30 Nature Medicine 2037.

Sinha, et al. (2025). Efficacy and Safety of GLP‐1 Receptor Agonists, Dual Agonists, and Retatrutide for Weight Loss in Adults With Overweight or Obesity - A Bayesian NMA. Obesity 33(11), 2064-2054.

Steenackers, et al. (2025, pre-publication). Pharmacotherapy for obesity - are we ready to select, tailor and combine pharmacotherapy to achieve more ambitious goals[Q] Frontiers Endocrinol., 16, 10.3389/fendo.2025.1569468.

Sutherby, It Is a Huge Market. The Pipeline Is Full. More GLP-1s Are On Their Way (Jun. 3, 2024) 34(6) Managed Healthcare Executive.

Tetelbaun, et al., The First Triple Agonist for Antiobesity - Retatrutide (pre-publication, 2024) Cardiology in Review. https://doi.org/10.1097/crd.0000000000000793.

 

[keangkong]

Here is an updated list, part II:

List of Reta Sources

Tewari, et al. (2025). Efficacy and safety of triple hormone receptor agonist retatrutide for the management of obesity - a systematic review and meta-analysis. Expert Rev. Clin. Pharmacology, 1–16, doi.org/10.1080/17512433.2025.2450254.

Urva, et al., (2022). LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes - a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial (2022) 400(10366 Lancet 1869.

Urva, et al. (2023) The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obesity Metabolism 25(9),2784–2788.

Xie, et al. (2024). Seven glucagon-like peptide-1 receptor agonists and polyagonists for weight loss in patients with obesity or overweight - an updated systematic review and network meta-analysis of randomized controlled trials. Metabolism, 161, 156038.

Yang, et al. (2025). Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction - A Systematic Review and Meta-Analysis. J. Diabetes.



Lilly Trials

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight (TRIUMPH-1).

A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2).

TRIUMPH-3 has already been completed. SJastreboff, et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New Engl. J. Med, 389(6), 514–526.

A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4).

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity (TRIUMPH-5).

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults (TRIUMPH-Outcomes).

• A Study to Measure Calorie Consumption and Usage in Participants With Obesity Using LY3437943.

• A Study of Retatrutide (LY3437943) on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes.

• Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1).

• Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2).

• Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)